Agios Pharmaceuticals | AGIO - Pre Utilidad Fiscal





Pre Utilidad Fiscal Cambio Fecha
AbbVie USD 4.38B 1.92B 2025-09
Agios Pharmaceuticals USD -109.06M 5.62M 2025-12
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Amgen USD 3.92B 2.35B 2025-09
Arrowhead Research USD 28.27M 7.85M 2025-12
Astellas Pharma JPY 133.96B 29.77B 2025-12
AstraZeneca USD 3.24B 117M 2025-09
Bayer EUR -1.16B 735M 2025-09
Biogen USD 557.3M 186.7M 2025-09
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Daiichi Sankyo JPY 106.73B 48.96B 2025-12
Eli Lilly USD 7.23B 456M 2025-09
Exelixis USD 252.69M 275K 2025-12
Gilead Sciences USD 3.64B 1.21B 2025-09
GlaxoSmithKline GBP 1.23B 1.23B 2025-12
Incyte USD 389.94M 92.37M 2025-12
Ionis Pharmaceuticals USD -228M 99M 2025-12
Merck USD 6.74B 22M 2025-09
Moderna USD -187M 631M 2025-09
Nektar Therapeutics USD -37.05M 15.27M 2024-09
Novartis USD 4.64B 445M 2025-12
Novartis USD 5.17B 637M 2025-09
Pfizer USD 3.33B 290M 2025-09
Puma Biotechnology USD 20.61M 24.76M 2024-09
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Roche Holding CHF 4.79B 3.01B 2025-06
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09